Kenya's health authorities have begun administering lenacapavir, a long-acting HIV prevention drug delivered by injection that offers protection for six months. The treatment will be available free of charge to eligible patients, making Kenya one of the first countries to introduce this new prevention therapy.
Lenacapavir, known as LEN, is a long-acting injectable administered once every six months. Named ‘Breakthrough of the Year’ by Science magazine in 2024, the drug is injected subcutaneously, just below the skin, in he lower abdomen or thighs.
